Targeted Therapy and Small Molecule Inhibitors

Targeted therapy aims to disrupt specific molecular pathways critical for cancer cell growth and survival. Small molecule inhibitors, a cornerstone of this approach, interfere with enzymes and proteins involved in cancer progression, such as tyrosine kinases and PI3K. These therapies offer higher specificity and reduced toxicity compared to conventional chemotherapy. Successful examples include imatinib for chronic myeloid leukemia and EGFR inhibitors for lung cancer. Resistance and off-target effects remain challenges, prompting research into next-generation inhibitors and combination regimens. Targeted therapies are central to personalized oncology, aligning treatment with individual genetic profiles for improved outcomes.

    Related Conference of Targeted Therapy and Small Molecule Inhibitors

    July 28-29, 2025

    45th Euro Congress on Cancer Science & Therapy

    Paris, France
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain
    October 22-23, 2025

    35th Experts Meet On Cancer Research & Therapy

    Paris, France
    October 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    Zurich, Switzerland
    November 20-21, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    November 24-25, 2025

    43rd World Cancer Conference

    Barcelona, Spain
    December 08-09, 2025

    13th Euro Breast Cancer and Therapeutics

    Aix-en-Provence, France
    February 19-20, 2026

    7th Cancer Diagnostics & Treatment Conference

    Miami, USA
    February 19-20, 2026

    8th International Conference on Women Oncology

    Miami, USA
    March 23-24, 2026

    16th World Congress on Breast Cancer Research & Therapies

    Aix-en-Provence, France

    Targeted Therapy and Small Molecule Inhibitors Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in